SRC and cholangiocarcinoma: In this report, inhibition of Src activity by dasatinib (at 0.1 μM) prevented cell migration of HuCCT1 by 80% (Figure 3), and suppressed HuCCT1 cell proliferation by 8–10% (data not shown), consistent with the inhibitory effect of dasatinib on CCA progression observed in vivo [48].